Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Title:Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Volume: 19 Issue: 4

Author(s): Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov

Affiliation:

Keywords: Glycogen synthase kinase 3, molecular design, cancer treatment, kinase inhibitors, Wnt pathway

Abstract: Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

Cite this article as:

Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov , Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors, Current Pharmaceutical Design 2013; 19(4) . https://dx.doi.org/10.2174/1381612811306040665